Abstract
BackgroundImmune checkpoint inhibitors (ICIs) have changed how cancer patients are treated, still, most patients ultimately develop resistance. Overcoming or preventing this resistance is a major clinical challenge. NBTXR3, when injected...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
